Effects of Vitamin D Supplementation on Cardiovascular and Glycemic Biomarkers.

What Was Tested

Researchers studied Vitamin D, K2, Magnesium and Zinc in this randomized controlled trial publication.

Methods and Results This was a prespecified, secondary analysis of the DAYLIGHT (Vitamin D Therapy in Individuals at High Risk of Hypertension) randomized controlled trial.

A meta-analysis of randomized controlled trials reporting biomarker changes after vitamin D supplementation was then performed.

Who Took Part

The study group was 6 individuals.

PubMed indexes the participants as teenagers, young adults, adults and middle-aged adults, both men and women.

How the Study Was Run

The design is described as randomized and double-blind.

Random assignment meant chance, not the researchers, decided who got Vitamin D, K2, Magnesium and Zinc and who got the comparison, which limits bias.

Blinding on both sides kept the individuals and researchers unaware of who received Vitamin D, K2, Magnesium and Zinc.

What Was Measured

Methods and Results This was a prespecified, secondary analysis of the DAYLIGHT (Vitamin D Therapy in Individuals at High Risk of Hypertension) randomized controlled trial.

PubMed files the paper under topics including Biomarkers, Blood Glucose, Cardiovascular Diseases, Dietary Supplements, Insulin Resistance, Lipids and Vitamin D.

The authors tagged it with the keywords high‐sensitivity C‐reactive protein and meta‐analysis.

What This Means in Plain Language

The paper is a randomized and double-blind study of Vitamin D, K2, Magnesium and Zinc in 6 individuals.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2021 (Journal of the American Heart Association), a journal based in England.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.